RAGE targeting attenuates smoke-induced inflammation

Information

  • Research Project
  • 10045988
  • ApplicationId
    10045988
  • Core Project Number
    R15HL152257
  • Full Project Number
    1R15HL152257-01A1
  • Serial Number
    152257
  • FOA Number
    PAR-18-714
  • Sub Project Id
  • Project Start Date
    7/15/2020 - 4 years ago
  • Project End Date
    6/30/2023 - a year ago
  • Program Officer Name
    PUNTURIERI, ANTONELLO
  • Budget Start Date
    7/15/2020 - 4 years ago
  • Budget End Date
    6/30/2023 - a year ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    7/12/2020 - 4 years ago
Organizations

RAGE targeting attenuates smoke-induced inflammation

Project Abstract Our preliminary studies have identified the receptor for advanced glycation end-products (RAGE) as a smoke- induced pattern recognition receptor with potent pro-inflammatory characteristics. Specific research demonstrated that RAGE is increased in the lung following first and secondhand smoke exposure and that transgenic mice that conditionally up-regulate RAGE manifest characteristics of a smoker?s lung in the absence of smoke. Exposure to tobacco smoke is the major cause of chronic obstructive pulmonary disease (COPD), the third leading cause of death, and it is characterized by debilitating inflammation and deleterious respiratory tissue loss. SAGEs are semi- synthetic glycosaminoglycan ethers that are potent modulators of inflammation in numerous animal models of human disease, and are in preclinical development for periodontitis, oral mucositis, and bladder inflammation. Importantly, SAGEs significantly inhibit interactions between RAGE and its many ligands necessary for signaling. The present proposal is the first to thoroughly assess the biology of RAGE signaling in the context of first and secondhand smoke exposure. A key innovation of this proposal is a collection of animal models that tightly control RAGE expression including RAGE null mice, tissue-specific transgenic mice that up-regulate RAGE, and mice harboring phosphorylation deficient RAGE alleles. This proposal also has significant impact due to its clinical potential to ameliorate smoke-induced inflammation and remodeling. The central hypothesis is that RAGE expression by pulmonary epithelium induces COPD by orchestrating widespread inflammation and parenchymal tissue loss. We further hypothesize that SAGEs inhibit RAGE-ligand signaling and potentially modify the course of tobacco-mediated disease via RAGE targeting. Two specific aims are proposed, and each uses advanced molecular methodologies employed by undergraduate students to test these hypotheses. The studies outlined in this proposal will validate RAGE signaling as a target pathway for the prevention or attenuation of COPD in individuals unable or unwilling to remove smoke exposure but may also help to clarify RAGE-mediated pathogenesis in a number of physiological processes.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R15
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
    300000
  • Indirect Cost Amount
    150000
  • Total Cost
    450000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    838
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NHLBI:450000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BRIGHAM YOUNG UNIVERSITY
  • Organization Department
    PHYSIOLOGY
  • Organization DUNS
    009094012
  • Organization City
    PROVO
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    846021001
  • Organization District
    UNITED STATES